Alexis Grande

Prof. Alexis Grande

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2003 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CBC. Bonini
C. Bonini
MGM. Grez
M. Grez
CTC. Traversari
C. Traversari
FCF. Ciceri
F. Ciceri
SMS. Marktel
S. Marktel
CBC. Bordignon
C. Bordignon

1 July 1994 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
Carlo PincelliCarlo Pincelli
Carlo Pincelli
CSCinzia Sevignani
Cinzia Sevignani
RMRossella Manfredini
Rossella Manfredini
AGAlexis Grande
Alexis Grande
FFFabrizio Fantini
Fabrizio Fantini
AGAlberto Giannetti
Alberto Giannetti

Verified
Journal Article
Open access
PDF file
FMFabiana Mammoli
Fabiana Mammoli
SCSara Castiglioni
Sara Castiglioni
SPSandra Parenti
Sandra Parenti
CCConcettina Cappadone
Concettina Cappadone
GFGiovanna Farruggia
Giovanna Farruggia
CFChiara Frassineti
Chiara Frassineti
Magnesium (Mg) is crucial for bone health. Low concentrations of Mg inhibit the activity of osteoblasts while promoting that of osteoclasts, with the final result of inducing osteopenia. Conversely, little is known about the effects of high concentrations of extracellular Mg on osteoclasts and osteoblasts. Since the differentiation and activation of these cells is coordinated by vitamin D3 (VD3), we investigated the effects of high extracellular Mg, as well as its impact on VD3 activity, in these cells. U937 cells were induced to osteoclastic differentiation by VD3 in the presence of supra-physiological concentrations (>1 mM) of extracellular Mg. The effect of high Mg concentrations was also studied in human bone-marrow-derived mesenchymal stem cells (bMSCs) induced to differentiate into osteoblasts by VD3. We demonstrate that high extra-cellular Mg levels potentiate VD3-induced osteoclastic differentiation, while decreasing osteoblastogenesis. We hypothesize that Mg might reprogram VD3 activity on bone remodeling, causing an unbalanced activation of osteoclasts and osteoblasts.

3 February 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PIPaola Italiani
Paola Italiani
EMEmilia M. C. Mazza
Emilia M. C. Mazza
DLDavide Lucchesi
Davide Lucchesi
ICIngrid Cifola
Ingrid Cifola
CGClaudia Gemelli
Claudia Gemelli
DBDiana Boraschi
Diana Boraschi
Monocytes/macrophages are key players in all phases of physiological and pathological inflammation. To understanding the regulation of macrophage functional differentiation during inflammation, we designed an in vitro model that recapitulates the different phases of the reaction (recruitment, initiation, development, and resolution), based on human primary blood monocytes exposed to sequential changes in microenvironmental conditions. All reaction phases were profiled by transcriptomic microarray analysis. Distinct clusters of genes were identified that are differentially regulated through the different phases of inflammation. The gene sets defined by GSEA analysis revealed that the inflammatory phase was enriched in inflammatory pathways, while the resolution phase comprised pathways related to metabolism and gene rearrangement. By comparing gene clusters differentially expressed in monocytes vs. M1 and vs. M2 macrophages extracted from an in-house created meta-database, it was shown that cells in the model resemble M1 during the inflammatory phase and M2 during resolution. The validation of inflammatory and transcriptional factors by qPCR and ELISA confirmed the transcriptomic profiles in the different phases of inflammation. The accurate description of the development of the human inflammatory reaction provided by this in vitro kinetic model can help in identifying regulatory mechanisms in physiological conditions and during pathological derangements.

1 May 2001 in Blood
Verified
Journal Article
Open access
ACAntonio Curti
Antonio Curti
MRMarina Ratta
Marina Ratta
SCSilvia Corinti
Silvia Corinti
GGGiampiero Girolomoni
Giampiero Girolomoni
FRFrancesca Ricci
Francesca Ricci
RLRoberto M. Lemoli
Roberto M. Lemoli
Exploration of the immunomodulatory activities of the multifunctional cytokine interleukin-11 (IL-11) has prompted several therapeutic applications. The immunomodulatory effects of IL-11 on human antigen-presenting cells and on T cells were investigated. IL-11 inhibited IL-12 production by activated CD14+ monocytes, but not by mature dendritic cells (DCs) stimulated via CD40 ligation. Moreover, IL-11 did not affect either DC maturation, as demonstrated by phenotypic analysis and evaluation of cytokine production, or DC generation from progenitor cells in the presence of specific growth factors. Molecular analysis demonstrated the expression of IL-11 receptor messenger RNA in highly purified CD14+ monocytes, CD19+ B cells, CD8+, and CD4+T cells, and CD4+CD45RA+ naive T lymphocytes. In keeping with this finding, IL-11 directly prevented Th1 polarization of highly purified CD4+CD45RA+naive T cells stimulated with anti-CD3/CD28 antibodies, as demonstrated by significant increases of IL-4 and IL-5, by significantly decreased interferon-γ production and by flow cytometry intracellular staining of cytokines. Coincubation of naive T cells with DCs, the most potent stimulators of Th1 differentiation, did not revert IL-11–mediated Th2 polarization. Furthermore, parallel experiments demonstrated that the activity of IL-11 was comparable with that induced by IL-4, the most effective Th2-polarizing cytokine. Taken together, these findings show that IL-11 inhibits Th1 polarization by exerting a direct effect on human T lymphocytes and by reducing IL-12 production by macrophages. Conversely, IL-11 does not exert any activity on DCs. This suggests that IL-11 could have therapeutic potential for diseases where Th1 responses play a dominant pathogenic role.

Verified
Journal Article
Open access
PDF file
Alexandre AnesiAlexandre Anesi
Alexandre Anesi
Luigi GeneraliLuigi Generali
Luigi Generali
LSLaura Sandoni
Laura Sandoni
SPSAMANTHA POZZI
SAMANTHA POZZI
AGAlexis Grande
Alexis Grande
Bone physiology relies on the delicate balance between resorption and formation of its tissue. Bone resorption depends on a process called osteoclastogenesis in which bone-resorbing cells, i.e., osteoclasts, are produced by the differentiation of more undifferentiated progenitors and precursors. This process is governed by two main factors, monocyte-colony stimulating factor (M-CSF) and receptor activator of NFκB ligand (RANKL). While the former exerts a proliferating effect on progenitors/precursors, the latter triggers a differentiation effect on more mature cells of the same lineage. Bone homeostasis requires a perfect space–time coordination of the involved signals. When osteoclastogenesis is poorly balanced with the differentiation of the bone forming counterparts, i.e., osteoblasts, physiological bone remodelling can turn into a pathological state, causing the systematic disruption of bone tissue which results in osteopenia or osteolysis. Examples of these conditions are represented by osteoporosis, Paget’s disease, bone metastasis, and multiple myeloma. Therefore, drugs targeting osteoclastogenesis, such as bisphosphonates and an anti-RANKL monoclonal antibody, have been developed and are currently used in the treatment of such diseases. Despite their demonstrated therapeutic efficacy, these agents are unfortunately not devoid of side effects. In this regard, a condition called osteonecrosis of the jaw (ONJ) has been recently correlated with anti-resorptive therapy. In this review we will address the involvement of osteoclasts and osteoclast-related factors in the pathogenesis of ONJ. It is to be hoped that a better understanding of the biological mechanisms underlying bone remodelling will help in the design a medical therapeutic approach for ONJ as an alternative to surgical procedures.